News

By Katherine Forsey, PhD | CMTA Chief Research Officer Current treatments for Charcot-Marie-Tooth disease (CMT) focus mainly on managing symptoms. But new advances in genetic therapies are changing the conversation and offering real hope for the future. CMTA is investing heavily ...

Tracking CMT4J from the Inside Out: What MRI Scans Are Showing So Far With CMTA support of $149,443, researchers at CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Elpida Therapeutics are investigating muscle fat fraction (MFF) as a biomarker for disease ...

CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has dosed the first healthy volunteer in a clinical trial of its investigational drug VCA 894A, an antisense oligonucleotide (ASO) the company designed to treat CMT2S. This milestone marks early ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to share that Kailee Ward, Genetic Counseling Assistant at CMTA’s Center of Excellence at the University of Iowa Hospitals and Clinics and Research Support ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Lisa Williams, MD, at UC Davis Health in Sacramento, California, as a CMTA Center of Excellence. Dr. Williams is a ...